S&S Healthcare Holding (ROCO:4198) Research & Development: NT$8.9 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4198 S&S Healthcare Holding Ltd ROCO:4198
54 GF Score
Price NT$38.05
GF Value NT$23.68
Valuation Significantly Overvalued
! 1 Warning Sign
View Full Analysis

What is S&S Healthcare Holding Research & Development?

S&S Healthcare Holding ROCO:4198 -5.11% 54 Research & Development is NT$8.9 Mil as of Dec. 2025. GuruFocus rates ROCO:4198 with a GF Score™ of 54/100 and a GF Value™ of NT$23.68 (Significantly Overvalued). The stock has 1 warning sign investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. S&S Healthcare Holding's Research & Development for the three months ended in Dec. 2025 was NT$2.5 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was NT$8.9 Mil.

S&S Healthcare Holding  (ROCO:4198) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

S&S Healthcare Holding Research & Development Related Terms

S&S Healthcare Holding Research & Development Historical Data

* Premium members only.

The historical data trend for S&S Healthcare Holding's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

S&S Healthcare Holding Research & Development Chart

S&S Healthcare Holding Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 24.33 21.38 15.11 10.04 8.89

S&S Healthcare Holding Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.72 2.13 2.17 2.14 2.45
ROCO:4198
54GF Score
S&S Healthcare Holding Ltd ROCO:4198
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

S&S Healthcare Holding Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$8.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of NT$8.9 Mil mean?
S&S Healthcare Holding (ROCO:4198) has a Research & Development of NT$8.9 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on S&S Healthcare Holding and its competitors.
Is S&S Healthcare Holding's Research & Development too high?
S&S Healthcare Holding's current Research & Development is NT$8.9 Mil. Overall, S&S Healthcare Holding has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does S&S Healthcare Holding's Research & Development compare to ABT and SYK?
S&S Healthcare Holding's Research & Development of NT$8.9 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on S&S Healthcare Holding and its competitors. S&S Healthcare Holding's current Research & Development is NT$8.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is S&S Healthcare Holding stock overvalued right now?
Based on GuruFocus' analysis, S&S Healthcare Holding (ROCO:4198) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$23.68, compared to a current price of NT$38.05 — trading 60.7% above its estimated fair value. The current Research & Development is NT$8.9 Mil. S&S Healthcare Holding's overall GF Score™ is 54/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For S&S Healthcare Holding (ROCO:4198), the current Research & Development is NT$8.9 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is S&S Healthcare Holding (ROCO:4198) Overvalued in 2026?

Based on GuruFocus' analysis, S&S Healthcare Holding stock appears to be overvalued. The current stock price of NT$38.05 is trading 60.7% above its estimated GF Value™ of NT$23.68. GuruFocus considers S&S Healthcare Holding to be Significantly Overvalued.

Key valuation signals for ROCO:4198:

  • Research & Development: NT$8.9 Mil
  • GF Value™: NT$23.68 vs. price of NT$38.05 (60.7% above fair value)
  • GF Score™: 54/100 with 1 warning sign

No single metric tells the full story. See the ROCO:4198 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

S&S Healthcare Holding Business Description

Address 7th Floor, Number 89, Xinhu 1st Road, Taipei, TWN, 114
S&S Healthcare Holding Ltd, formerly Swissray Global Healthcare Holding Ltd is involved in providing DR systems designed for any application in general radiography. The product divisions of the company cover Swissray DDR systems, Novadaq, and EZ2GO. The main business projects of the company and its subsidiaries are the research and development, manufacturing, sales, and maintenance services of high-end medical equipment and the manufacturing and sales of basic medical equipment.
54GF Score

Get the complete analysis for ROCO:4198

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$38.05
Price
NT$23.68
GF Value